Prelude Therapeutics Inc PRLD.OQ PRLD.O is expected to show a rise in quarterly revenue when it reports results on March 9 (estimated) for the period ending December 31 2025
The Wilmington Delaware-based company is expected to report a 775.0% increase in revenue to $35 million from $4 million a year ago, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for Prelude Therapeutics Inc is for a loss of 3 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Prelude Therapeutics Inc is $4.00, about 28.2% above its last closing price of $3.12
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.36 | -0.37 | -0.26 | Beat | 28.8 |
Jun. 30 2025 | -0.44 | -0.44 | -0.41 | Beat | 6.7 |
Mar. 31 2025 | -0.47 | -0.47 | -0.42 | Beat | 10.3 |
Dec. 31 2024 | -0.46 | -0.38 | Beat | 18 | |
Sep. 30 2024 | -0.47 | -0.47 | -0.43 | Beat | 8.9 |
Jun. 30 2024 | -0.43 | -0.43 | -0.46 | Missed | -7 |
Mar. 31 2024 | -0.48 | -0.48 | -0.42 | Beat | 13.4 |
Dec. 31 2023 | -0.49 | -0.49 | -0.46 | Beat | 6.1 |
This summary was machine generated March 6 at 12:59 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)